Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Update

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) saw a significant drop in short interest in the month of May. As of May 29th, there was short interest totaling 90,033 shares, a drop of 37.1% from the May 14th total of 143,119 shares. Based on an average trading volume of 105,286 shares, the days-to-cover ratio is currently 0.9 days. Currently, 2.6% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ACXP shares. Wall Street Zen raised Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $31.00.

Acurx Pharmaceuticals Trading Down 1.9%

ACXP opened at $1.54 on Wednesday. The stock has a fifty day simple moving average of $2.11 and a two-hundred day simple moving average of $2.71. The company has a market cap of $6.62 million, a price-to-earnings ratio of -0.38 and a beta of -2.09. Acurx Pharmaceuticals has a 12-month low of $1.33 and a 12-month high of $21.00.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). On average, analysts predict that Acurx Pharmaceuticals will post -1.94 EPS for the current year.

Hedge Funds Weigh In On Acurx Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ACXP. Jane Street Group LLC bought a new position in Acurx Pharmaceuticals in the fourth quarter worth $27,000. Geode Capital Management LLC bought a new position in shares of Acurx Pharmaceuticals during the fourth quarter valued at $31,000. Millennium Management LLC bought a new position in shares of Acurx Pharmaceuticals during the fourth quarter valued at $103,000. Finally, Armistice Capital LLC bought a new position in shares of Acurx Pharmaceuticals during the second quarter valued at $551,000. Institutional investors own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).